Payment overview · 2025
General Payments
$20,171.83
93 reported records · 23 companies
Healthcare provider profile · identity verified
Neil Kumar, MD
Allopathic & Osteopathic Physicians|General Practice · ROSEBURG, OR · NPI 1003813015
Verified facts
What the public records show
CMS Open Payments records show Neil Kumar, MD received $20,171.83 in general payments during 2025 across 93 reported records.
Travere Therapeutics, Inc. accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Filspari, Jardiance, Kerendia, Lokelma.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Auryxia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Travere Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Filspari as an associated drug or biological on 8542 records involving 2693 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Filspari by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $5,196.74 | 25.8% | 12 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $5,192.70 | 25.7% | 11 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $4,854.63 | 24.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,465.85 | 17.2% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $309.98 | 1.5% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $217.09 | 1.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.64 | 1.0% | 9 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $133.35 | 0.7% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $88.94 | 0.4% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $80.33 | 0.4% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $57.62 | 0.3% | 2 | 2025 |
| Vericel Corporation | Unresolved — no canonical attribution shown | $56.69 | 0.3% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $49.52 | 0.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $49.08 | 0.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.94 | 0.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.70 | 0.1% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.63 | 0.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.30 | 0.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $22.43 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.97 | 0.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.53 | 0.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $19.10 | 0.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $19.07 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,340.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,465.00 | 5 |
| Travel and Lodging | $4,064.47 | 8 |
| Food and Beverage | $2,173.28 | 74 |
| Education | $129.08 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XPHOZAH 30 MG Normalized: xphozah 30 mg |
Drug | Ardelyx, Inc. | $5,136.19 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $3,351.38 | 8 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $1,234.72 | 7 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $309.98 | 6 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $217.09 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $145.53 | 5 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $133.35 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $88.94 | 4 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $80.33 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.11 | 4 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $57.62 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $56.51 | 6 | 2025 |
Source payment records
|
|||||
| ARANESP Normalized: aranesp |
Biological | Amgen Inc. | $53.94 | 2 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $50.45 | 4 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $49.52 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $49.08 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| MACI Normalized: maci |
Biological | Vericel Corporation | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| PARSABIV Normalized: parsabiv |
Drug | Amgen Inc. | $32.06 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $27.70 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| Filspari filspari |
2025 | Filspari | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
84 | 34 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Travere Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Filspari open payments reported associated product |
CMS Open Payments — General Payments 8542 supporting records · 2693 recipient NPIs · example record 1244395624 |
Filspari · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 1033 | 276 |
| Furosemide | Furosemide | 844 | 244 |
| Calcitriol | Calcitriol | 603 | 156 |
| Bumetanide | Bumetanide | 591 | 144 |
| Losartan Potassium | Losartan Potassium | 555 | 165 |
| Clonidine Hcl | Clonidine Hcl | 389 | 107 |
| Gabapentin | Gabapentin | 306 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 61 |
| Prosol | Parenteral Amino Acid 20% No.1 | 222 | suppressed |
| Lisinopril | Lisinopril | 212 | 54 |
| Allopurinol | Allopurinol | 204 | 53 |
| Midodrine Hcl | Midodrine Hcl | 189 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 156 | 45 |
| Spironolactone | Spironolactone | 156 | 40 |
| Calcium Acetate | Calcium Acetate | 150 | 48 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 150 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 115 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 20 |
| Metolazone | Metolazone | 98 | 33 |
| Torsemide | Torsemide | 94 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 22 |
| Carvedilol | Carvedilol | 86 | 27 |
| Lokelma | Sodium Zirconium Cyclosilicate | 84 | 34 |
| Myrbetriq | Mirabegron | 84 | 17 |
| Farxiga | Dapagliflozin Propanediol | 73 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 68 | 25 |
| Azithromycin | Azithromycin | 67 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 19 |
| Prednisone | Prednisone | 64 | 27 |
| Methylprednisolone | Methylprednisolone | 59 | 32 |
| Omeprazole | Omeprazole | 59 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 43 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 20 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 53 | suppressed |
| Pregabalin | Pregabalin | 49 | 13 |
| Levofloxacin | Levofloxacin | 44 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 11 |
| Atenolol | Atenolol | 39 | suppressed |
| Febuxostat | Febuxostat | 39 | suppressed |
| Rayaldee | Calcifediol | 39 | suppressed |
| Jardiance | Empagliflozin | 38 | 11 |
| Ondansetron Odt | Ondansetron | 38 | 26 |
| Cinacalcet Hcl | Cinacalcet Hcl | 35 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 17 |
| Kerendia | Finerenone | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 13 |
| Famotidine | Famotidine | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | 14 |
| Fluconazole | Fluconazole | 25 | 19 |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Colchicine | Colchicine | 23 | 11 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 13 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 15 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Eplerenone | Eplerenone | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Auryxia | Ferric Citrate | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Filspari | Sparsentan | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20,171.83 · 93 records | Travere Therapeutics, Inc. | ACTHAR, ARANESP, CRYSVITA, EVENITY, FARXIGA, FUROSCIX, Fabhalta, Filspari, Gazyva, IBSRELA, INJECTAFER, JARDIANCE, KRYSTEXXA, Kerendia, LOKELMA, MACI, OTEZLA, Ozempic, PARSABIV, REPATHA, REZDIFFRA, TARPEYO, ULTOMIRIS, Vafseo, Vanrafia, Wegovy, XIFAXAN, XPHOZAH 30 MG, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error